Gallant
San Diego, California, United States · Biotechnology, Health Care, Other · 35 employees
Gallant is a regenerative medicine company pioneering veterinary therapies that restore health at the source. We’re developing a pipeline of off-the-shelf mesenchymal stem cell (MSC) therapies to address chronic conditions in dogs and cats—including feline chronic gingivostomatitis (FCGS), osteoarthritis, chronic kidney disease, and atopic dermatitis. Our first product, based on a proprietary uter
Funding history
- Funding Round — $10.2M — Jul 2025
- Series series b — $18.0M — Jun 2025
- Funding Round — $25.5M — Aug 2024
- Funding Round — $15.0M — Jan 2024
- Series series a — $15.0M — Jan 2024
Recent signals
- Jul 11, 2025: Raised $10.2M
- Jun 30, 2025: Raised $18.0M in Series series b
- Aug 16, 2024: Raised $25.5M
- Jan 30, 2024: Raised $15.0M
- Jan 08, 2024: Raised $15.0M in Series series a
- Aug 05, 2019: Raised $7.0M
See plans & pricing → Track Gallant’s funding, hiring, and signals — with verified contacts — on Fundz.